IMV (T:IMV) has notable insider buying

IMV Inc. (IMV) has a high amount of executive buying compared to its small-cap peers over the past three months.

Alfred Smithers, a Director, acquired 5,000 Common Shares on an indirect ownership basis for registered holder Iona Resources Holdings Limited at a price of $6.740 through the public market on June 22nd, 2018. This represents a $33,700 investment into the company's shares and an account share holdings change of 6.6%.

IMV is in the Biotechnology & Medical Research Sub Industry Group under the Healthcare Sector.

Imv Inc, formerly known as Immunovaccine Inc is a Canada-based clinical-stage immuno oncology company. The Company develops products based on its vaccine enhancement platform with a primary focus on T lymphocytes (T cell) activating therapies for cancer. The Company's DepoVax adjuvanting/delivery platform produces immune response that has a specific and sustained immune effect and enables the Company to pursue vaccine candidates in cancer, infectious diseases and other vaccine applications. The DepoVax platform is used in multiple vaccine candidates, including over two-cancer vaccine candidates that have completed Phase I clinical trials. Its lead cancer vaccine, DPX- Survivac, is tested in a company-sponsored Phase II trial in lymphoma and a Phase Ib trial in ovarian cancer. Its infectious disease vaccine against respiratory syncytial virus (RSV) is in a Phase I clinical trial in Halifax, Nova Scotia.